Dx & Vx Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
89
- Stock Symbol
-
180400
- Investments
-
3
- Share Price
-
$1.54
- (As of Monday Closing)
Dx & Vx General Information
Description
Dx & Vx Co Ltd is a bio-healthcare company operating in the following business segments: Medical Diagnosis, Healthcare, and New Drug Development. The majority of its revenue is generated from the Healthcare segment, which utilizes diagnostic technology to provide integrated biohealthcare solutions for microbiome-based diseases, and offers health functional foods for prevention, over-the-counter and prescription drugs for treatment, and lifestyle and hygiene products for management. The Medical Diagnosis segment provides preimplantation, prenatal, neonatal, and adult genomic testing and microbiome analysis services, and the New Drug Development business is involved in the research and development of COVID vaccines and treatment, microbiome respiratory vaccine, and mRNA anticancer vaccine.
Contact Information
Website
www.dxvx.comCorporate Office
- 10th Floor 234, Digital-ro
- Geumcheon-gu
- Seoul
- South Korea
Corporate Office
- 10th Floor 234, Digital-ro
- Geumcheon-gu
- Seoul
- South Korea
Dx & Vx Stock Performance
As of 16-Nov-2026, Dx & Vx’s stock price is $1.54. Its current market cap is $152M with 98.4M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.54 | $1.55 | $0.89 - $3.64 | $152M | 98.4M | 52.9K | -$0.27 |
Dx & Vx Financials Summary
As of 30-Jun-2026, Dx & Vx has a trailing 12-month revenue of $18.1M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 112,979 | 135,752 | 79,981 | 161,172 |
| Revenue | 18,070 | 20,628 | 24,880 | 31,545 |
| EBITDA | (16,501) | (19,382) | (36,305) | (17,357) |
| Net Income | (17,377) | (20,405) | (34,471) | (21,020) |
| Total Assets | 69,665 | 107,551 | 49,124 | 77,549 |
| Total Debt | 9,489 | 33,325 | 29,046 | 30,902 |
Dx & Vx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Dx & Vx Patents
Dx & Vx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026205991-A1 | Novel compounds with glp-1 receptor agonist activity | Pending | 27-Mar-2025 | ||
| WO-2026205992-A1 | Novel probiotic culture having preventive and therapeutic activity against stress, depression, and hearing loss | Pending | 27-Mar-2025 | ||
| EP-4831287-A1 | Novel circular rna synthesis method using rna ligase | Pending | 18-Dec-2023 | ||
| US-11865480-B2 | Nucleic acid purification device and nucleic acid purification method | Active | 07-May-2019 | ||
| US-20200353393-A1 | Nucleic acid purification device and nucleic acid purification method | Active | 07-May-2019 | B01D39/2065 |
Dx & Vx Signals
Dx & Vx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Dx & Vx Investments & Acquisitions (3)
Dx & Vx’s most recent deal was a Later Stage VC with Oxford Vacmedix for . The deal was made on 16-May-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Oxford Vacmedix | 16-May-2025 | Later Stage VC | Drug Discovery | ||
| Korea Biopharmaceuticals | 16-Sep-2022 | Merger/Acquisition | Drug Discovery | ||
| Oxford Cancer Biomarkers | 08-May-2017 | Later Stage VC | Discovery Tools (Healthcare) |
Dx & Vx ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
Dx & Vx Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Korea Biopharmaceuticals | Chungbuk, South Korea | 1995 |
Dx & Vx FAQs
-
When was Dx & Vx founded?
Dx & Vx was founded in 2001.
-
Where is Dx & Vx headquartered?
Dx & Vx is headquartered in Seoul, South Korea.
-
What is the size of Dx & Vx?
Dx & Vx has 89 total employees.
-
What industry is Dx & Vx in?
Dx & Vx’s primary industry is Drug Discovery.
-
Is Dx & Vx a private or public company?
Dx & Vx is a Public company.
-
What is Dx & Vx’s stock symbol?
The ticker symbol for Dx & Vx is 180400.
-
What is the current stock price of Dx & Vx?
As of 16-Nov-2026 the stock price of Dx & Vx is $1.54.
-
What is the current market cap of Dx & Vx?
The current market capitalization of Dx & Vx is $152M.
-
What is Dx & Vx’s current revenue?
The trailing twelve month revenue for Dx & Vx is $18.1M.
-
What is Dx & Vx’s annual earnings per share (EPS)?
Dx & Vx’s EPS for 12 months was -$0.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process